INmune Bio (INMB) announced the successful completion of its first full-scale pilot commercial manufacturing run of CORDStrom, an off-the-shelf, allogeneic, umbilical cord tissue-derived mesenchymal stromal cell therapy for the treatment of Recessive Dystrophic Epidermolysis Bullosa. This milestone, achieved at the Cell and Gene Therapy Catapult’s state-of-the-art Manufacturing Innovation Centre in Stevenage, United Kingdom, marks a critical step toward regulatory submissions and keeps the Company on track for filing a Marketing Authorization Application in the UK during the first half of 2026 followed by a Biologics License Application in the US.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Inmune Bio’s Earnings Call: Progress Amid Challenges
- Inmune Bio: Strategic Position and Growth Potential Amid Leadership Change and Promising Pipeline
- INmune Bio Reports Q2 2025 Results and Strategic Updates
- INmune Bio CEO RJ Tesi retires, David Moss succeeds
- INmune Bio reports Q2 EPS ($1.05), consensus (38c)